Why I Just Bought More of This Beaten-Down 7%-Yielding Dividend Stock
Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period.This might seem like the kind of stock you'd want to avoid. However, I have a different perspective about Pfizer. Here are three reasons why I just bought more of this beaten-down stock.Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces. The company's COVID-19 product sales have declined sharply from their peak at the height of the pandemic. Just how much have sales fallen? Last year, Pfizer's COVID-19 vaccine Comirnaty generated sales of $5.35 billion. In 2022, the total was $37.8 billion. Continue reading
Pick a time frame -- year to date, last 12 months, last three years, last five years, or last 10 years. Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period.
This might seem like the kind of stock you'd want to avoid. However, I have a different perspective about Pfizer. Here are three reasons why I just bought more of this beaten-down stock.
Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces. The company's COVID-19 product sales have declined sharply from their peak at the height of the pandemic. Just how much have sales fallen? Last year, Pfizer's COVID-19 vaccine Comirnaty generated sales of $5.35 billion. In 2022, the total was $37.8 billion.
